Focused On-demand Library for Zinc finger CCCH domain-containing protein 14

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q6PJT7

UPID:

ZC3HE_HUMAN

Alternative names:

Mammalian suppressor of tau pathology-2; Renal carcinoma antigen NY-REN-37

Alternative UPACC:

Q6PJT7; A8MY46; B4DXU8; B4DZW7; B4E2H4; G3V5R4; Q6MZU4; Q6PJ32; Q6PUI6; Q6PUI8; Q86TQ5; Q86TW0; Q86TW1; Q8NCT6; Q8NCZ3; Q8TDE2; Q9HAC9; Q9Y5A0

Background:

Zinc finger CCCH domain-containing protein 14, also known as Mammalian suppressor of tau pathology-2 and Renal carcinoma antigen NY-REN-37, plays a crucial role in poly(A) tail length control in neuronal cells by binding to polyadenosine RNA oligonucleotides. Its unique function underscores its importance in post-transcriptional regulation, a key process in gene expression.

Therapeutic significance:

This protein's involvement in Intellectual developmental disorder, autosomal recessive 56, highlights its potential as a target for therapeutic intervention. Understanding the role of Zinc finger CCCH domain-containing protein 14 could open doors to potential therapeutic strategies, offering hope for patients and advancing the field of genetic disorders.